MTN-030/IPM-041: A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings

Document Type

Data Set

Publication Date

9-27-2024

Abstract

The International Partnership for Microbicides (IPM), which was acquired by the Population Council in 2022, is the developer of the dapivirine vaginal ring and a multipurpose prevention technology (MPT) vaginal ring containing dapivirine and levonorgestrel. Two Phase 1 trials, evaluating pharmacokinetics, safety, bleeding patterns, acceptability, adherence and the vaginal microenvironment of the dapivirine levonorgestrel ring were conducted at sites in the United States by the Microbicide Trials Network (MTN). These data sets support the bleeding and acceptability analyses from one of the clinical trials (MTN-030).

DOI

10.7910/DVN/BYPUJC

Language

English

Project

International Partnership for Microbicides (IPM)

https://doi.org/10.7910/DVN/BYPUJC

Link to Full Text

Share

COinS